OBGYN.net Highlights the Most Important Research Expected in 2013 - Applied Clinical Trials

ADVERTISEMENT

See our 2012 Buyers Guide Digital Edition.
Find Pharma Search Engine
OBGYN.net Highlights the Most Important Research Expected in 2013


OBGYN.net Highlights the Most Important Research Expected in 2013

PR Newswire

NORWALK, Conn., Feb. 26, 2013 /PRNewswire/ -- UBM Medica US announces OBGYN.net spoke with leaders of seven obstetric and gynecologic societies about the most eagerly anticipated research and developments on the horizon in 2013. Developments cited include the results of the ELITE trial, which examines the effect of hormone therapy on heart health and brain function; the FDA's decision on two non-hormonal therapies for hot flashes; and evidence-based guidelines for the care of women with pregnancy complicated by hypertension and preeclampsia.

Additionally, James T. Breeden, MD, the president of the American Congress of Obstetrics and Gynecology (ACOG), America's largest ob/gyn society, reasserted the organization's commitment to family planning services in 2013.

Experts also commented on the most important developments of 2012, which included American Society for Reproductive Medicine's (ASRM) removal of the 'experimental' label from the procedure of oocyte cryopreservation, and discoveries into the complex genetic processes involved in ovarian cancer.

Surveyed societies include the American Congress of Obstetrics and Gynecology (ACOG), American Society for Reproductive Medicine (ASRM), Society for Maternal and Fetal Medicine (SMFM), North American Menopause Society (NAMS), Society of Gynecologic Oncology (SGO), American Urogynecologic Society (AUS), and the Royal College of Obstetricians and Gynaecologists (RCOG).

About UBM Medica US
Addressing today' s healthcare information needs, UBM Medica US, delivers strategic, integrated communications solutions and comprehensive reach—online, in print, and via custom programs. Improving the effectiveness of healthcare through information and education, UBM Medica US provides unbiased clinical, practical, and business information for physicians, providers, payers, and patients around the world. Through journals, magazines, websites, online communities, drug databases, digital events, and other valuable resources, UBM Medica US also delivers comprehensive communication solutions for the pharmaceutical and related industries. Websites include CancerNetwork.com, ConsultantLive.com, DiagnosticImaging.com, MusculoskeletalNetwork.com, OBGYN.net, PhysiciansPractice.com, PsychiatricTimes.com and SearchMedica.com. UBM Medica US is part of UBM Connect – which provides marketing services across a number of communities, the largest of which are healthcare, medical device design and advanced manufacturing. UBM Connect also includes UBM Studios, the global leader in interactive digital environments. UBM Connect is a UBM plc company. For more information, visit http://www.UBMMedicaUS.com

Media contact:
Jason J. Golden
Content Marketing Manager
203-523-7040
jason.golden@ubm.com

SOURCE UBM Medica US

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
94%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
6%
View Results
Untitled Document

Click here